Find Academic Supervisors

• Neurodegenerative Diseases
• Motor Neuron Disease (MND)
• Frontotemporal Dementia (FTD)
• +7 more

Dr. Rebecca San Gil is a Lecturer at the School of Medical Sciences , University of Sydney, Australia. She leads the NeuroMolecular Discovery Group within the Neuroscience theme and is a member of the Charles Perkins Centre . Her research focuses on the molecular mechanisms underlying neurodegenerative diseases such as motor neuron disease (MND) and frontotemporal dementia (FTD) , with an emphasis on protein aggregation, stress responses, and therapeutic discovery. PhD, University of Wollongong (2018) Postdoctoral Research, Queensland Brain Institute (2018–2025) Endeavour Research Fellow (University College London) Her research spans molecular biology , neurosciences , and biochemistry , integrating techniques like genome-wide CRISPR screening , multi-omics analysis , and translational research . Key themes include the role of molecular chaperones , heat shock response , and protein folding dynamics in mitigating neurodegeneration. Dr. San Gil’s recent publications (2016–2025) highlight her work on TDP-43 pathology , heat shock proteins , and therapeutic strategies across ALS/FTD models. She has received awards such as the FightMND Early Career Research Fellow and the Sydney Dementia Network Future Research Leader Award (Travel Support Scheme) in 2025. Scientific Awards : FightMND Early Career Research Fellow, Sydney Dementia Network Future Research Leader Award (2025) Dr. San Gil actively mentors researchers like Celine CHYE and collaborates with institutions globally. Her team welcomes new members to explore neurodegenerative disease biology and therapeutic discovery .

Soeren LienkampView profile

Assistant Professor

• Molecular Biology
• Genetics
• Developmental Biology
• +5 more

Prof. Dr. Soeren Lienkamp is an Assistant Professor at the Institute of Anatomy , Faculty of Medicine , University of Zurich . His work bridges digital education and genetic research , focusing on enhancing medical teaching through innovative formats. Research Interests : Genetics, developmental biology, kidney disease modeling, CRISPR applications, digital medical education, and advanced microscopy. Methodologies : Combines Xenopus tropicalis models, deep learning , and bioengineering to study genetic kidney disorders and improve diagnostic tools. Publication Trends : His recent articles highlight predictable genome editing , 3D imaging technologies , and mechanistic insights into kidney and eye development. Earlier works focus on ciliary function , Wnt signaling , and metabolic stress in renal cells.

Scott L. DiamondView profile

Professor

• Mechanobiology
• Thrombolysis
• Coagulation
• +10 more

Scott L. Diamond is the Arthur E. Humphrey Professor of Chemical and Biomolecular Engineering and Bioengineering at the University of Pennsylvania's School of Engineering and Applied Sciences. He serves as Director of the Penn Center for Molecular Discovery, Director of the Penn Biotechnology Masters Program (one of the largest in the country with over 130 students), and Associate Director of the Institute for Medicine and Engineering (IME). His laboratory is located in the Roy and Diana Vagelos Laboratories at 3340 Smith Walk, 1020 Vagelos Research Laboratories, Philadelphia, PA. Diamond's research spans multiple interconnected fields in blood biology and biotechnology. His work focuses on mechanobiology, thrombolysis, coagulation, bioadhesion, gene therapy, drug/device development, proteomics, drug discovery, systems biology, and microfluidics. His laboratory has developed numerous specialized microfluidic devices for studying blood clotting under various flow conditions, including 8-channel devices for high-throughput clotting assays, side-view devices for clot structure analysis, stenosis devices for high shear clotting assays, and impingement-post devices for studying von Willebrand factor fibers. Diamond's research group has pioneered approaches to model and predict blood function using systems biology principles. His team has developed computational models that integrate reaction-transport phenomena with platelet signaling networks to predict thrombus formation under flow. These models have enabled the development of 'virtual blood' computer simulations that can predict the effectiveness of anticoagulation drugs for individual patients, contributing significantly to personalized medicine approaches in hemostasis and thrombosis. His extensive publication record demonstrates a consistent focus on understanding the fundamental mechanisms of blood clot formation and dissolution. Recent work has emphasized microfluidic approaches for point-of-care diagnostics, patient-specific modeling of platelet function, and the development of novel therapeutic strategies for thrombotic disorders. His research bridges engineering principles with clinical hematology to address significant challenges in cardiovascular medicine. NSF National Young Investigator Award NIH FIRST Award American Heart Association Established Investigator Award AIChE Allan P. Colburn Award George Heilmeier Excellence in Research Award Elected Fellow of the Biomedical Engineering Society (BMES) Diamond has secured significant research funding, including a $2.8 million NIH grant for 'Blood Systems Biology' and a $9.5 million NIH grant for the Penn Center for Molecular Discovery. His laboratory has developed numerous microfluidic devices for blood analysis and has collaborated extensively with clinicians and industry partners. Diamond has served on advisory committees for NSF, NIH, AHA, and NASA, and has consulted extensively for industry and government. With over 180 publications and patents, his work has significantly advanced the understanding of blood clotting mechanisms and the development of diagnostic and therapeutic approaches for thrombotic disorders.

Ravi ShuklaView profile

Professor

• Nanobiotechnology
• Bioscience
• Medical Biotechnology
• +6 more

Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).

Bonnie BergerView profile

Professor

• Compressive Genomics
• Network Inference
• Structural Bioinformatics
• +4 more

Bonnie Berger is the Simons Professor of Mathematics at the Massachusetts Institute of Technology and head of the Computation and Biology group at MIT's Computer Science and AI Lab. She holds additional appointments as an Associate Member of the Broad Institute, Faculty member of Harvard/MIT Health Science & Technology, and Affiliated Faculty of Harvard Medical School. Her career has been dedicated to pioneering computational approaches in molecular biology, where she has been instrumental in defining the field. Professor Berger's research focuses on designing algorithms to extract biological insights from large-scale data sets. Her work spans Compressive Genomics, Network Inference, Structural Bioinformatics, Genomic Privacy, and Medical Genomics. She actively collaborates with experimental biologists to maximize the power of computation for biological discovery, developing methods that address the challenges of modern high-throughput biological data. Her recent publications demonstrate a strong trend toward integrating machine learning with structural biology and genomic privacy. The articles show increasing sophistication in using deep learning for protein structure prediction, developing privacy-preserving techniques for genomic data sharing, and creating efficient algorithms for massive biological data sets. Her work bridges theoretical computer science with practical biological applications. Professor Berger's scientific recognition includes: Election to the National Academy of Sciences (2021) ISCB Accomplishments by a Senior Scientist Award SIAM Sonya Kovalevsky Lecture Prize Fellowships in ACM, ISCB, AMS, and other prestigious societies Multiple RECOMB Test of Time Awards NIH Margaret Pittman Director's Award She has mentored numerous students who have gone on to make significant contributions in computational biology, including Ellen Zhong, Yun William Yu, and Hyunghoon Cho. Her lab receives substantial research funding supporting projects in genomic privacy, structural bioinformatics, and compressive algorithms for biological data. Professor Berger serves on the Executive Editorial Board of the Journal of Computational Biology and multiple other editorial boards. The Computation and Biology group at MIT CSAIL, which she leads, is at the forefront of developing computational methods for biological discovery. The group combines expertise in algorithms, machine learning, and biology to tackle fundamental challenges in genomics and structural biology. They are currently organizing the Machine Learning in Structural Biology workshop at NeurIPS 2025, highlighting their leadership in this rapidly evolving interdisciplinary field.

Anja LiekfeldView profile

Adjunct Professor

• Ophthalmology
• Optical Device Technology
• Refractive Surgery
• +3 more

Anja Liekfeld serves as Adjunct Professor of Ophthalmic Optics/Optical Device Technology at Brandenburg University of Technology since 2018 while concurrently holding the position of Chief Physician at Klinikum Ernst von Bergmann's Department of Ophthalmology in Potsdam since 2009. Her dual roles bridge academic research in optical engineering with clinical ophthalmology practice, focusing on technological advancements for eye care delivery. Her educational foundation includes medical studies at Essen and Berlin Universities (1986-1992), state examination (1992), ophthalmology residency at Charité (1994-1997), specialist certification (1997), doctoral degree magna cum laude (1997), and habilitation on capsular bag models for cataract research (2007). Liekfeld's research centers on optical properties of intraocular lenses, clinical applications of medical devices in ophthalmology, refractive surgery techniques (laser and IOLs), cataract surgery technologies, glaucoma diagnostics/therapy, and gerontological ophthalmology. Her work emphasizes translating engineering principles into clinical solutions for complex vision correction challenges. Over 25 years of publications reveal evolving expertise from molecular glaucoma research to advanced IOL development. Recent work focuses on multifocal/toric lenses, dysphotopsia analysis, and visual outcomes measurement, demonstrating consistent innovation at the optics-clinical interface with practical applications for patient care. Her accolades include: DOG/SFO Travel Grant (2000) DGII Best Presentation Award (2008) DOC Gold Medal (2011) Focus Magazine Top Doctor (2013-2021) Stern Magazine Top Doctor (2022) As an educator, she trains surgical assistants, diet technicians, and operating room staff while teaching ophthalmology to visually impaired pedagogy students at Humboldt University. She conducts international wet labs for surgeons and optometrists, serves on editorial boards for Concept and Karger Kompass Ophthalmologie, and reviews for major ophthalmology journals. Active in professional societies including DGII, ESCRS, DOG, BBAG, and BDOC, she chairs Brandenburg's Ophthalmology Examination Board since 2021 and serves on the board of Die Augenchirurginnen e.V. Her research utilizes human capsular bag models for cataract studies and maintains focus on improving optical device performance in clinical settings.

Bob Beitle Jr.View profile

Professor

• Biochemical Engineering
• Bioseparation
• Fermentation
• +5 more

Dr. Bob Beitle Jr. is a Professor of Chemical Engineering and Senior Associate Vice Chancellor for Research and Innovation at the University of Arkansas. He joined the department in 1993, earned tenure in 1998, and was promoted to Full Professor in 2006. His research spans biochemical engineering , bioseparation , fermentation , and adaptive technology for the disabled , with significant work on protein purification, catalytic nanoparticles, and sustainable bioprocesses. Education: BS, MS, PhD in Chemical Engineering from the University of Pittsburgh (1987, 1991, 1993) Dr. Beitle's research combines experimental and computational approaches, focusing on peptide-directed nanoparticle synthesis and biocatalysis . His recent publications highlight advancements in MOF-based separations , CO2 capture materials , and viral detection platforms . He has secured grants like the CAREER Award and led projects in industrial partnerships and student development . Scientific contributions include multiple patents in bioseparation and software interfaces. Awards span decades: teaching honors (1988–2007) and mentorship recognition . He serves on the Cell and Molecular Biology Program Advisory Committee and the Executive Committee for the Biochemical Technology Division of ACS . Lab initiatives involve genomic data-driven affinity tail design and membrane-assisted fermentation systems .

Su Ryon ShinView profile

Assistant Professor

• Bioengineering
• Tissue Engineering
• 3D Bioprinting
• +7 more

Dr. Su Ryon Shin is an Assistant Professor in the Division of Engineering in Medicine at Harvard Medical School and Brigham and Women's Hospital (BWH) in Cambridge, MA. She leads an active research laboratory focused on bioengineering, tissue engineering, and regenerative medicine, with particular expertise in 3D bioprinting, biomaterials, and organ-on-a-chip technology. Her research interests span biohybrid robotics, decellularized extracellular matrix, stem cell-based tissue engineering, and volumetric muscle regeneration . Dr. Shin's work integrates advanced biomaterials with cellular systems to create innovative solutions for tissue regeneration and disease modeling. She has pioneered approaches using human stem cell-derived materials for volumetric tissue regeneration and developed biohybrid neuromuscular robots powered by living cardiac muscle cells. Her publication record demonstrates consistent productivity with over 180 publications, including numerous first/senior author papers in high-impact journals like Science Robotics, Advanced Materials, and Nature Reviews Bioengineering . Her work shows a clear progression from fundamental biomaterials development to increasingly complex tissue engineering applications and translational research. Dr. Shin has received significant recognition including being named a 2025 BWH Health & Technology Innovation Awardee , Highly Cited Researcher 2024 by Web of Science, and multiple Stepping Strong Innovator Awards (2015, 2018, 2020). Her research has been featured in Nature Reviews Bioengineering for breakthrough work on biohybrid robots. She actively mentors students and postdocs, with former lab members accepted to prestigious programs like MIT's PhD program in Chemical Engineering. Her collaborative approach is evident through numerous interdisciplinary projects with researchers across Harvard Medical School, BWH, and international institutions.

Marc SchneiderView profile

Professor

• Colloidal drug delivery systems
• Nanoparticle and microparticle engineering
• Nanotechnology in pharmacy
• +3 more

Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +5 more

João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .

Allan DavidView profile

Professor

• Smart Materials
• Nanomedicine
• Cancer Research
• +4 more

Allan David serves as the John W. Brown Professor of Chemical Engineering and Associate Dean for Research at Auburn University's Samuel Ginn College of Engineering. His leadership extends across academic administration and cutting-edge nanomedicine research, with a focus on translating laboratory discoveries into clinical applications. His educational foundation includes: Ph.D. in Chemical Engineering, University of Maryland B.S. in Chemical Engineering, University of Maryland Dr. David's research program pioneers nanomedicine applications through the development of smart materials for cancer diagnostics and therapy. His work spans nanoparticle-based MRI contrast agents , ocular drug delivery systems , and vaccine delivery platforms , with particular emphasis on optimizing physicochemical properties for targeted biological interactions. Current projects address critical healthcare challenges including safer contrast agents for patients with kidney impairment and precision cancer targeting mechanisms. Analysis of his 15 most recent publications reveals a cohesive research trajectory centered on magnetic nanoparticles and biomimetic delivery systems . The work demonstrates increasing translational focus, evolving from fundamental nanoparticle characterization (2020-2021) to clinically relevant applications like ocular delivery and cancer theranostics (2022-2024), culminating in commercialization efforts through NanoXort, LLC. Dr. David has secured significant research funding including an $184,773 grant from the Alabama Department of Economic and Community Affairs (ADECA) for developing cardiovascular MRI agents. He leads collaborative efforts that bridge chemical engineering with biomedical innovation, notably co-founding NanoXort, LLC to commercialize safer MRI contrast agents addressing gadolinium toxicity concerns for renal-impaired patients. His laboratory operates at the intersection of chemical engineering and medicine, focusing on nanoparticle-cell interactions and targeted delivery systems. The research group maintains strong industry partnerships through the NanoXort startup, which has secured $1 million NSF funding to advance MRI contrast agent technology toward clinical implementation.

David AckerleyView profile

Professor

• Enzymes
• Synthetic biology
• Microbiology
• +4 more

Professor David Ackerley (Victoria University of Wellington) is a leading microbiologist and enzyme engineer specializing in directed evolution of bacterial enzymes for biotechnological applications. As Biotechnology Programme Director since 2006, he lectures in foundational courses like BTEC101 and BTEC201. Academic rank: Professor of Biotechnology Institutional affiliation: Victoria University of Wellington Research focus areas: Microbial Biotechnology, Drug Discovery, Synthetic Biology His research employs Darwinian evolutionary principles to engineer enzymes with enhanced activities, particularly targeting non-ribosomal peptide synthetases and nitroreductases for antibiotic development and cancer therapy. Recent work explores metagenomic domain substitution in pyoverdine biosynthesis and Purpuramine R from marine sponges. Key publications demonstrate innovations in metagenomic library construction , CRISPR screening for regeneration genes, and structural characterization of engineered enzymes. His team has developed NTR 2.0 , a high-efficacy nitroreductase for targeted cell ablation. Current research projects include: Clean solutions from dirty genes: Plastic-degrading enzyme discovery Engineering enzymes for CAR T-cell-chemotherapy synergy Repurposing niclosamide against Gram-negative superbugs Grants from the Health Research Council of New Zealand, Royal Society of New Zealand, and Cancer Society of NZ support his work. Collaborations span biomedical research, synthetic biology, and environmental applications.

Anne-Sophie ChauvinView profile

Senior Lecturer

• Supramolecular Chemistry
• Inorganic Chemistry
• Lanthanide Chemistry
• +7 more

Anne-Sophie Chauvin is a Senior Lecturer and Researcher at École Polytechnique Fédérale de Lausanne (EPFL), School of Basic Sciences, within the Institute of Chemical Sciences and Engineering and the Supramolecular Chemistry Laboratory. She actively engages in supramolecular and inorganic chemistry, focusing on f-element (lanthanides and actinides) coordination polymers and luminescent bioprobes for biological and technological applications, including invisible inks and dye-sensitized solar cells. PhD in Bioinorganic Chemistry from University Paris V-René Descartes (thesis on Nitrile Hydratase mimetics) Postdoctoral work at University of Geneva on chiral alcohol configuration analysis Habilitation à Diriger des Recherches (HDR) from University René Descartes (2006) Her research spans Lanthanide and Actinide Chemistry , Luminescence , Coordination Polymers , Metallacages , and Photovoltaic Materials . Recent publications emphasize catalytic spiro stereocenter formation, actinide coordination polymers, and photoredox-enabled biomolecule functionalization. She has supervised PhD students including Andrei Andreichenko , Julien Andrès , Steve Comby , and Aurélien Willauer . Recognitions include Fellowship of the Royal Society of Chemistry (FRSC) and membership in the Swiss Chemical Society (SCS). Current roles include teaching General and Analytical Chemistry to first-year Pharmacy and Biology students at the University of Lausanne (UNIL), overseeing practical sessions, and serving on the EPFL School of Basic Sciences Faculty Council.

Alan WinstonView profile

Professor

• HIV
• Central Nervous System Complications
• Mental Health
• +5 more

Professor Alan Winston serves as Professor of Genito-Urinary Medicine within the Department of Infectious Disease at Imperial College London's Faculty of Medicine. He concurrently holds a Consultant Physician position at St. Mary's Hospital, London, where he directs the HIV and GU clinical trials unit managing over 20 active studies. His clinical and academic work bridges patient care with cutting-edge research in HIV comorbidities. Winston qualified from Glasgow University and completed specialized training in general medicine and HIV care across the UK and Australia. This foundation supports his current focus on non-infectious complications in the modern antiretroviral era, particularly neurological and mental health aspects. His research prominently explores central nervous system complications in HIV, cognitive impairment mechanisms, and mental health disparities including depression and anxiety. He investigates multimorbidity patterns in aging HIV populations and develops person-centered approaches to reduce stigma. His work integrates clinical trials, cohort studies like POPPY, and mixed-methods research to address quality-of-life challenges beyond viral suppression. Analysis of his 2024-2025 publications reveals three dominant trends: (1) neurocognitive effects of specific antiretrovirals (dolutegravir, bictegravir), (2) psychosocial determinants of cognitive performance, and (3) systemic barriers in mental healthcare access for HIV patients. The POPPY cohort study serves as a critical data source across multiple publications examining aging, polypharmacy, and multimorbidity. Winston leads the POPPY study tracking comorbidities in HIV-positive individuals over time and directs the St. Mary's clinical trials unit conducting therapeutic research. His team includes clinical project managers, trials coordinators, and research staff like PhD candidate Merle Henderson. While specific grants aren't detailed, his management of 20+ concurrent studies indicates substantial research funding from sources including European AIDS Clinical Society collaborations. His laboratory and clinical operations are centered at the Winston Churchill Wing of St Mary's Campus, with affiliations to the Section of Virology and St Mary's Clinical Trials Centre. He contributes to European guideline development, notably statin use recommendations for cardiovascular prevention in HIV patients.

• Oncology
• Molecular Biology
• Targeted Therapies
• +3 more

Livio Trusolino is a Professor in the Department of Oncology at the University of Turin, affiliated with the Institute for Cancer Research and Treatment (IRCCS) in Candiolo. His research focuses on mechanisms of neoplastic transformation, growth factor receptor signaling, and preclinical models of targeted therapies, particularly in colorectal cancer. He leads courses such as 'Targeted Therapies in Colon Cancer' and contributes to the MD-PhD Program in Medicine. His work integrates molecular profiling (proteomics, genomics) with experimental models like patient-derived xenografts to study drug sensitivity and resistance. Key collaborations include projects on KRAS mutations, EGFR blockade, and drug combination therapies. He chairs academic bodies within the Department of Oncology and oversees the Molecular Pharmacology Laboratory. Recent research highlights include identifying biomarkers for therapeutic response and elucidating adaptive mutability in cancers. His contributions bridge basic science and clinical applications, advancing precision oncology strategies for colorectal cancer.